The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience

CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117

Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research